Medicinal Chemistry Journal of Medicinal Chemistry

Tricyclic pteridinone yields an oral HPK1 inhibitor that pairs with anti-PD-1

  • Structure-guided scaffold hopping and ring optimization from a known diaminopyrimidine carboxamide HPK1 chemotype gave a new tricyclic pyrido[2,1-h]pteridin-6-one core.
  • Lead 29 is highly potent with strong kinase selectivity, blocks SLP-76 phosphorylation and boosts T-cell activation in Jurkat cells and human PBMCs.
  • It shows good oral exposure and, combined with anti-PD-1 in the CT26.WT syngeneic model, clearly improves tumor control.
Points Based on the abstract

Tricyclisation plausibly pre-organises the hinge-binding conformation and cuts the entropic cost, so the design logic is easy to follow. The harder test is selectivity within the MAP4K family, notably GLK, and against T-cell kinases such as LCK, where off-target activity could undercut the immune benefit. The combination result also lacks a monotherapy arm and an inactive analogue to show it is on-target.